Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Not yet recruiting 6Completed 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × irinotecan sucrosofate × Clear all
NCT02785068 2017-01-11

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Merrimack Pharmaceuticals

Phase 1/2 Withdrawn
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡